Ajmal Aseem

Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
Clinical Trials Healthcare & Pharmaceuticals News

AstraZeneca’s Gefurulimab Shows Major Promise in Late-Stage Myasthenia Gravis Trial

AstraZeneca

AstraZeneca announced that its novel nanobody, gefurulimab, has successfully met its primary and all secondary endpoints in the PREVAIL Phase III trial for adults with generalized myasthenia gravis (gMG). The results showed that the once-weekly, self-administered treatment delivered statistically significant and clinically meaningful improvements in daily living activities for patients with this rare autoimmune disease.

Clinical Trials Healthcare & Pharmaceuticals News

New Study Shows 87% Reduction in RSV-Related Doctor Visits for Infants Treated with Sanofi’s BEYFORTUS®

sanofi

A groundbreaking real-world study has revealed that Beyfortus (nirsevimab-alip) significantly reduces the incidence of respiratory syncytial virus (RSV) disease in infants. The largest of its kind in the United States, the study demonstrated an 87% reduction in RSV cases requiring a visit to a doctor or hospital and a 98% decrease in hospitalizations among infants who received the treatment.

Clinical Trials News Oncology

AstraZeneca’s Tagrisso with Chemotherapy Shows Significant Survival Benefit in Advanced Lung Cancer

AstraZeneca

AstraZeneca announced groundbreaking results from its FLAURA2 Phase III trial, revealing that Tagrisso (osimertinib) combined with chemotherapy offers a statistically significant and clinically meaningful improvement in overall survival for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).

Research Biotechnology

Three Person IVF: UK Welcomes Healthy Babies, Preventing Transmission of Genetic Disease

baby feet

Eight healthy babies have been born in the UK using a revolutionary “three-person IVF” technique called mitochondrial donation. This groundbreaking procedure, led by scientists at Newcastle University, successfully prevents the transmission of incurable, inherited genetic diseases from mother to child, offering new hope to families worldwide.

Clinical Trials News Oncology

Pfizer and Astellas Announce Landmark Survival Benefit with XTANDI in Prostate Cancer Trial

pfizer news

Pfizer and Astellas report groundbreaking Phase 3 EMBARK trial results showing XTANDI® (enzalutamide) plus leuprolide significantly improves overall survival in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) and high-risk biochemical recurrence. This marks the first time an androgen receptor inhibitor-based therapy has shown a definitive survival benefit in this specific patient population, offering new hope for extending lives through early and effective treatment.

Regulatory Approval News

FDA Approves Updated Label for Lilly’s Alzheimer’s Drug Kisunla (donanemab-azbt), Offering a Safer Dosing Schedule

Eli Lilly and Company

The U.S. Food and Drug Administration (FDA) has officially approved an updated label for Eli Lilly’s groundbreaking Alzheimer’s drug, Kisunla (donanemab-azbt). This significant update introduces a new, more gradual dosing schedule specifically designed to enhance patient safety by reducing the risk of amyloid-related imaging abnormalities (ARIA), a critical side effect.

Healthcare & Pharmaceuticals Business News

GSK Acquires Efimosfermin, Bolstering Liver Disease Pipeline with Potential Best-in-Class Treatment

GSK - GlaxoSmithKline

GSK has finalized its acquisition of efimosfermin, a promising new therapeutic for steatotic liver disease. The deal, valued at up to $2 billion, positions GSK to potentially launch a best-in-class treatment for MASH and ALD by 2029, significantly enhancing its hepatology portfolio.